Vaporox, Inc.
Vaporox is dedicated to advancing wound care through innovative solutions like Vaporous Hyperoxia Therapy (VHT). Their FDA-cleared technology uses hydrating vapor/mist and concentrated oxygen to promote rapid healing of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and other complex wounds. The company's mission is to improve patient outcomes, support healthcare providers, and reduce the costs associated with chronic wound management.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Vaporous hyperoxia treatment system (FDA-cleared localized therapy unit)
A Class II, FDA-cleared localized wound therapy system that delivers alternating cycles of low-frequency ultrasonic-generated hydrating vapor and concentrated oxygen inside a localized treatment chamber for adjunctive treatment of chronic wounds.
Disposable treatment kits and treatment solution bottles
Single-use disposable kits supplied in multi-item boxes and treatment solution bottles sold in multi-bottle units intended for use with the ultrasonic vaporizer.
Vaporous hyperoxia treatment system (FDA-cleared localized therapy unit)
A Class II, FDA-cleared localized wound therapy system that delivers alternating cycles of low-frequency ultrasonic-generated hydrating vapor and concentrated oxygen inside a localized treatment chamber for adjunctive treatment of chronic wounds.
Disposable treatment kits and treatment solution bottles
Single-use disposable kits supplied in multi-item boxes and treatment solution bottles sold in multi-bottle units intended for use with the ultrasonic vaporizer.
Services
On-site setup and tailoring of the therapy system to facility workflows to minimize disruption during deployment.
Hands-on training sessions, demonstrations, and training videos for clinical staff covering device operation, treatment protocol, and patient handling.
Access to a support team, documented error codes, troubleshooting guides, maintenance procedures and a technical contact for equipment swap and escalations.
Supply and fulfillment of single-use disposable kits, treatment solution bottles, brochures and measurement tools with an automatic reorder/auto-ship option.
Operational program to provide devices without upfront capital expense, support for billing under a Category 1 CPT code, and assistance with reimbursement workflows.
Partnership on IRB-reviewed studies, retrospective analyses, and support for preparing case studies and peer-reviewed manuscripts.
On-site setup and tailoring of the therapy system to facility workflows to minimize disruption during deployment.
Hands-on training sessions, demonstrations, and training videos for clinical staff covering device operation, treatment protocol, and patient handling.
Access to a support team, documented error codes, troubleshooting guides, maintenance procedures and a technical contact for equipment swap and escalations.
Supply and fulfillment of single-use disposable kits, treatment solution bottles, brochures and measurement tools with an automatic reorder/auto-ship option.
Operational program to provide devices without upfront capital expense, support for billing under a Category 1 CPT code, and assistance with reimbursement workflows.
Partnership on IRB-reviewed studies, retrospective analyses, and support for preparing case studies and peer-reviewed manuscripts.
Expertise Areas
- Adjunct wound therapy clinical implementation
- Clinical trial management and IRB study conduct
- Regulatory clearance and FDA 510(k) compliance
- Clinical outcomes analytics and wound measurement
Key Technologies
- Low-frequency, non-contact ultrasonic mist generation
- Concentrated topical oxygen therapy (COT)
- Localized treatment chamber hardware
- Digital wound area and volume measurement (photography and standardized rulers)
News & Updates
A retrospective analysis of 53 chronic wounds treated with Vaporox’s VHT technology demonstrates a 62% healing rate within 16 weeks, highlighting the therapy's efficacy in accelerating wound healing.
A study showing an 84% closure rate within 20 weeks for non-healing diabetic foot wounds treated with Vaporox’s VHT in conjunction with standard care.
A retrospective analysis of 53 chronic wounds treated with Vaporox’s VHT technology demonstrates a 62% healing rate within 16 weeks, highlighting the therapy's efficacy in accelerating wound healing.
A study showing an 84% closure rate within 20 weeks for non-healing diabetic foot wounds treated with Vaporox’s VHT in conjunction with standard care.